Specialist-Oriented Products Now Account for a Growing Share of Blockbuster Drugs.
Despite changes in the pharmaceutical industry and a marked slowdown in the number of new drugs launched, the blockbuster model of drug development is alive and well. Since 1986, the number of blockbuster drugs has grown continuously, and this growth shows no signs of a slowdown.
Specialist-oriented products now account for a growing share of blockbuster drugs. How will this changing product mix impact blockbuster sales? What factors must companies consider to ensure accurate forecasting for these higher-priced products? The full exploitation of blockbuster potential, both within therapeutic areas and across disease indications, has been important to industry growth. Will this trend continue even as the number of new products continues to languish? Which therapeutic areas offer the greatest potential for indication proliferation? Fears that pharmacogenomics spells the imminent demise of blockbusters are unfounded. Which recent blockbusters have proved this premise to be wrong? How can pharma companies broaden their forecasting vision for these new pharmacogenomic drugs?
Under-forecasting of blockbuster products threatens to limit the commercial potential of the industry, and higher standards of forecasting are needed. What industry factors are causing this tendency to under-forecast? How can companies combat under-forecasting in order to identify the true potential of their blockbuster products?
Scope of the report:
-- Pharmaceutical industry growth in the blockbuster era: an examination of how the industry has managed to sustain healthy growth despite the drop in new product launches.
-- Blockbusters, 2005 and 1995: an analysis of blockbusters past and present and how the mix of products has changed.
-- Why blockbuster numbers continue to rise: a discussion of indication proliferation and under-forecasting of blockbuster potential.
-- Impact of pharmacogenomics: a recent chronology of events and a discussion of the arrival and impact of pharmacogenomic blockbusters.
-- Outlook: a discussion of the dangers of under-forecasting and the need to improve forecasting going forward in order to more readily identify potential blockbusters.
Johnson & Johnson
Procter & Gamble
For more information visit http://www.researchandmarkets.com/reports/c46412
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 4, 2006|
|Previous Article:||39% Of Digital Printers Say Their Digital Printing Volumes Are Increasing "a Little" or "a Lot".|
|Next Article:||Parkinson's Disease is Poised to become a Significant Public Health Burden as the Population Ages.|